City Therapeutics
Develops next-generation RNAi therapeutics and engineering platform for multiple disease areas
$99.5MSeries B
Role not disclosedI
Invus
Activity from announced rounds
Activity in this selectionUnited States · Jun 30, 2026 · Jun 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $192M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionContraline
Develops hormonal and non-hormonal male contraceptives for men and couples globally
$92.5MSeries B
Role not disclosed